Methylphenobarbital

From Wikipedia, the free encyclopedia - View original article

Methylphenobarbital
Methylphenobarbital.png
Systematic (IUPAC) name
5-phenyl-5-ethyl-
1-methylbarbituric acid
Clinical data
AHFS/Drugs.comInternational Drug Names
MedlinePlusa605022
Pregnancy cat.?
Legal statusClass B (UK) Schedule IV (US)
Routes?
Pharmacokinetic data
Bioavailability?
Protein binding70-76%
MetabolismHepatic
Half-life34 hours
Excretion?
Identifiers
CAS number115-38-8 YesY
ATC codeN03AA01
PubChemCID 8271
DrugBankDB00849
ChemSpider7972 YesY
UNII5NC67NU76B YesY
KEGGD00700 YesY
ChEBICHEBI:6758 YesY
ChEMBLCHEMBL45029 YesY
Chemical data
FormulaC13H14N2O3 
Mol. mass246.3 g/mol
 YesY (what is this?)  (verify)
 
Jump to: navigation, search
Methylphenobarbital
Methylphenobarbital.png
Systematic (IUPAC) name
5-phenyl-5-ethyl-
1-methylbarbituric acid
Clinical data
AHFS/Drugs.comInternational Drug Names
MedlinePlusa605022
Pregnancy cat.?
Legal statusClass B (UK) Schedule IV (US)
Routes?
Pharmacokinetic data
Bioavailability?
Protein binding70-76%
MetabolismHepatic
Half-life34 hours
Excretion?
Identifiers
CAS number115-38-8 YesY
ATC codeN03AA01
PubChemCID 8271
DrugBankDB00849
ChemSpider7972 YesY
UNII5NC67NU76B YesY
KEGGD00700 YesY
ChEBICHEBI:6758 YesY
ChEMBLCHEMBL45029 YesY
Chemical data
FormulaC13H14N2O3 
Mol. mass246.3 g/mol
 YesY (what is this?)  (verify)

Methylphenobarbital (INN), also known as mephobarbital (USAN, JAN) and mephobarbitone (BAN), marketed under brand names such as Mebaral, Mephyltaletten, Phemiton, and Prominal, is a drug which is a barbiturate derivative and is used primarily as an anticonvulsant,[1] but also as a sedative and anxiolytic. It is the N-methylated analogue of phenobarbital and has similar indications, therapeutic value, and tolerability.

Approval history[edit]

The company further stated in a letter on its website [2] that under the FDA's Unapproved Drugs Initiative, FDA is no longer willing to allow the drug to be grandfathered. A new drug application would have needed to have been submitted to gain marketing approval, which would have taken an estimated five years, during which time patients would be required to change their therapies in any case. The last available tablets bore an expiration date of March 31, 2012, and the drug will no longer be available in the US when supplies are depleted.

Overdose[edit]

Symptoms of overdose of mephobarbital include confusion, decrease in or loss of reflexes, somnolence, fever, irritability, hypothermia, poor judgment, shortness of breath or slow/troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness.

See also[edit]

References[edit]

  1. ^ S. D. Shorvon, David R. Fish, Emilio Perucca, W. Edwin Dodson, ed. (2004). The Treatment of Epilepsy (2nd ed.). Blackwell. ISBN 0-632-06046-8. 
  2. ^ Letter from Lundbeck to prescribers